The scale of the problem the trial targets is difficult to overstate. Cancer patients and survivors experience pain at rates far exceeding those of the general population, and that pain erodes quality of life, disrupts sleep, fuels anxiety and depression, and can undermine the very treatments meant to cure or control the disease. Evidence-based, multi-modal pain care strategies, which combine pharmacologic approaches with behavioral, rehabilitative, and self-management techniques, already exist and are endorsed by clinical guidelines. Yet the authors of the ASCENT protocol point out that knowing what works is not the same as delivering it. Existing care models frequently fail to account for the preferences, support systems, and social needs of individual patients, and those failures fall hardest on populations facing structural barriers to access.

That is why the trial focuses specifically on rural-dwelling and/or Hispanic cancer patients with moderate to severe pain receiving care at one of eight participating sites. Rural patients often live hours from specialty pain services, and Hispanic patients may confront language barriers, distrust, and cost-related obstacles that make consistent follow-up nearly impossible. Social determinants of health, the economic and social conditions that shape a person’s ability to obtain care, are treated in ASCENT not as background noise but as a core clinical variable. The intervention is explicitly designed to identify and address these social determinant of health related access barriers alongside the pain itself, a dual mandate that distinguishes it from most prior pain management trials.

The mechanics of the intervention are deceptively simple. Participants randomized to the intervention arm receive a structured series of telephone and video calls over six months, delivered not by a physician but by a carefully constructed dyad: a Pain Care Manager paired with a Community Health Worker. The Pain Care Manager brings clinical expertise in pain assessment and management, while the Community Health Worker brings cultural connection, local knowledge, and the trust that comes from shared community experience. This pairing is the engine of the trial’s equity strategy. The community health worker can surface social needs that a patient might never disclose in a busy oncology clinic, from transportation problems to housing instability to difficulty affording medications, and can help translate the care plan into something that actually fits the patient’s life.

Each participant’s journey through the intervention begins with initial calls designed to characterize their pain and cancer histories, their management preferences, and their social determinant of health needs. From that assessment, the team constructs a Personalized Pain Management Program for each participant, one that is explicitly aligned both with the best available evidence and with the patient’s own stated preferences. The program is not a static document handed to the patient at discharge; it is refined during subsequent calls over the six-month period, allowing the dyad to adjust strategies as pain evolves, as side effects emerge, or as social circumstances shift. This iterative, preference-sensitive approach reflects a growing recognition in pain medicine that adherence depends less on the theoretical superiority of a treatment than on whether the patient actually wants and is able to follow it.

On the measurement side, the trial is rigorous and patient-centered. All participants, in both the intervention and control arms, complete outcome assessments at baseline and at three and six months. The battery captures pain, physical functioning, mood, sleep, quality of life, and pain catastrophizing, the pattern of catastrophic thinking about pain that is known to amplify suffering and disability. The primary outcome is pain itself, assessed with the Brief Pain Inventory, one of the most widely validated instruments in the field. Beyond patient-reported measures, the trial will track healthcare utilization outcomes, including hospitalizations and emergency care visits, providing a hard-edged test of whether better ambulatory pain management actually keeps patients out of emergency departments and hospital beds. That utilization data matters enormously for any future effort to scale the model, because payers and health systems will want evidence that proactive remote care offsets downstream acute care costs.

The theoretical scaffolding of the trial is the collaborative care model, an approach originally developed for depression treatment in primary care and since validated across dozens of chronic conditions. In its classic form, collaborative care embeds a care manager within a primary care team, supported by a consulting specialist who reviews cases and advises on treatment escalation. ASCENT adapts this architecture for cancer pain and strips away the requirement that patients physically travel to a clinic. By delivering the model entirely through telephone and video contact, the trial tests whether the collaborative care engine can run at a distance, reaching patients for whom the traditional clinic-based version is geographically or socially out of reach. If it works, the implications extend well beyond the two populations studied here, since the barriers faced by rural and Hispanic patients, distance, cost, language, and trust, are barriers that many other groups share.

The trial is supported by the National Institutes of Health through the NIH HEAL Initiative under award number R33CA278594, a funding stream created to accelerate solutions to the nation’s overlapping pain and opioid crises. That provenance is significant. Cancer pain management sits at a difficult intersection in American medicine: opioids remain an essential tool for many patients with moderate to severe cancer-related pain, yet the broader crackdown on opioid prescribing has made clinicians increasingly hesitant to prescribe, and patients with cancer have sometimes been caught in the crossfire of policies designed for other populations. A multi-modal, remotely delivered model that combines pharmacologic and non-pharmacologic strategies, monitors safety, and tailors care to individual preferences represents one plausible path through that thicket, offering comprehensive relief without relying on any single class of medication.

The research team itself reflects the trial’s community-embedded philosophy. In addition to investigators from Mayo Clinic sites in Rochester and Phoenix, the University of Oklahoma’s TSET Health Promotion Research Center and Stephenson Cancer Center, Yale University School of Medicine, Indiana University School of Medicine, the Regenstrief Institute, and The Ohio State University College of Medicine, the author list includes Deisy Canon Lovera of HACER, Hispanic Advocacy and Community Empowerment through Research, a St. Paul, Minnesota organization dedicated to community-driven research with Hispanic populations. The ASCENT Team consortium includes additional staff members who will carry out the day-to-day work of recruitment, assessment, and intervention delivery. The authors have also committed to a dissemination policy that extends beyond academic publication: findings will be shared at conferences and in peer-reviewed journals, and preliminary results will be sent to participants themselves in a final newsletter thanking them for their contribution, a small but meaningful gesture of reciprocity toward the patients whose data will drive the science.

For now, ASCENT remains a protocol rather than a result, and the oncology community will have to wait for the trial’s outcome data to know whether this model delivers. But the design alone signals where the field is heading. The future of cancer pain management, the trial suggests, may belong not to any single analgesic but to hybrid systems that pair clinical expertise with community trust, that treat social barriers as treatable clinical problems, and that meet patients where they are, literally, through the phone in their pocket. If the six-month intervention reduces pain, improves function and mood, and keeps patients out of emergency rooms, it would offer a potentially scalable, remote template for equitable pain care at a moment when the demand for such models has never been clearer.

Subject of Research: A randomized clinical trial protocol testing a digitally-enabled collaborative care intervention for cancer pain management in rural-dwelling and Hispanic patients

Article Title: Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain Management (ASCENT): Protocol for a Randomized Clinical Trial

Article References: Minteer, S. A., Austin, J. D., Clark, M. M., Morrison, E. J., Herrin, J., Tilburt, J., Pachman, D. R., Ruddy, K. J., Nelson, A., Podratz, J., Frick, M., Daus, L., Kroenke, K., Doubeni, C. A., Lovera, D. C., ASCENT Team, Dozois, D., Hein, J., Lulf, J., … Cheville, A. (2026). Achieving Safe, Comprehensive, Digitally-Enabled Cancer Pain Management (ASCENT): Protocol for a Randomized Clinical Trial. BMC Cancer. https://doi.org/10.1186/s12885-026-17122-8

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17122-8

Keywords: cancer pain, randomized clinical trial, collaborative care model, community health worker, telehealth, health equity, rural health, Hispanic health, social determinants of health, pain management, NIH HEAL Initiative, Mayo Clinic

The Collaborative Care Model is a specific form of behavioral health integration in which primary care teams are joined by two additional roles: care managers, who coordinate and track treatment for patients with common psychiatric conditions, and psychiatric consultants, who advise on the harder cases without requiring every patient to secure an appointment with a psychiatrist. A registry tracks each patient’s symptoms over time, allowing the team to adjust treatment systematically rather than waiting for patients to return on their own. The approach emerged from randomized trials, most famously in the treatment of late-life depression, and has accumulated an unusually robust evidence base spanning clinical outcomes, implementation science, and health economics.

The numbers cited in the perspective are striking. Studies of the model report a return on investment of roughly six to one, driven largely by reductions in overall medical spending, not just psychiatric costs. Patients with poorly controlled behavioral health conditions, particularly those with chronic comorbidities, tend to generate higher total medical expenditures and worse outcomes, so treating depression and anxiety effectively in primary care ripples through the rest of the health system. Perhaps more remarkable is the workforce mathematics: by concentrating psychiatric expertise at the level of consultation rather than one-on-one visits, the model multiplies the impact of each psychiatrist’s effort by as much as seven times. In an era when the behavioral health workforce is limited and geographically concentrated, that leverage is not a luxury but a necessity.

So why has real-world adoption lagged so far behind the evidence? The authors point squarely at fee-for-service reimbursement, the dominant payment architecture in American medicine. In 2017, the Centers for Medicare and Medicaid Services created billing codes specifically designed to reimburse collaborative care and related behavioral health integration activities, a genuine step forward. But not all state Medicaid agencies or commercial payers have adopted those codes, reimbursement rates vary widely, and billing stipulations are inconsistent across payer types and practice settings. The codes themselves are administratively demanding, requiring clinicians to track the minutes spent delivering collaborative care each month and then determine which codes to bill at month’s end. That complexity alone deters many practices from starting.

The deeper problem, however, is structural. Under fee-for-service, the primary care organization must front the investment required to implement the model, hiring care managers, building registries, and reorganizing workflows, while the savings from reduced total cost of care flow to the payer. Behavioral health, meanwhile, competes for investment capital against more lucrative fee-for-service revenue generators, often procedures. In other words, the party that pays the costs is not the party that reaps the returns. The authors argue that simply expanding the billing codes across payers, while worthwhile, is unlikely to be sufficient to drive adoption at the scale the evidence justifies.

The opportunity, they suggest, lies in the ongoing migration of primary care into value-based payment arrangements: risk-bearing provider organizations, value-based primary care companies, capitated programs for beneficiaries dually eligible for Medicare and Medicaid, and demonstration models from the CMS Innovation Center aimed at medically complex patients. To organize their recommendations, the authors use the framework of alternative payment models developed by the Health Care Payment Learning and Action Network, which sorts payment arrangements into four categories of increasing provider accountability. Category 1 is traditional fee-for-service; category 2 adds links to quality and value, such as pay-for-performance; category 3 introduces shared savings and shared risk; and category 4 is full population-based payment.

For each stage, the authors propose a tailored incentive strategy. In pure fee-for-service settings, payers should universally adopt the collaborative care codes, offer more favorable fee schedules with reduced administrative burden, particularly for medically complex populations and youths, and consider upfront infrastructure payments to offset implementation costs. In pay-for-performance arrangements, those measures would be supplemented by incorporating the model as a structural quality measure and adding behavioral health outcome metrics such as benchmarks for treatment response or remission. In shared savings and shared risk arrangements, the recommendation is a hybrid: maintain some fee-for-service reimbursement while allowing providers to share downstream savings, and remove the model’s codes from primary care capitation fee reduction lists, at least during early implementation, because returns may not materialize until the second year or beyond.

At the most advanced stage, full population-based payment, providers theoretically capture the savings themselves, reducing the need for separate fee-for-service reimbursement. But the authors draw a technical distinction here: the return on investment in collaborative care comes substantially through medical cost savings, not merely behavioral health savings, so the inherent incentive is strongest under comprehensive population-based payment rather than condition-specific arrangements. Even in these advanced models, they caution, implementation incentives remain warranted because the financial returns take time to realize. Across all four categories, the authors add cross-cutting policy recommendations: minimizing patient cost-sharing, harmonizing billing stipulations across payers to reduce administrative burden, pushing all state Medicaid agencies to adopt the codes, and providing technical assistance, information technology support, and staffing help, as North Carolina and other states have begun to do.

What makes the argument timely is the convergence of pressures on primary care. Value-based arrangements reward outcomes and efficiency, which is precisely what collaborative care delivers, yet the perspective notes a perverse detail: in many accountable care organizations, the model’s fee-for-service codes appear on lists of primary care capitation fee reductions, cutting that payment by as much as one hundred percent. Despite this, the authors maintain that collaborative care remains the most advantageous behavioral health integration model available, given its demonstrated success across research and real-world settings in treatment access, clinical outcomes, and return on investment. The payment architecture, in their view, is the last remaining bottleneck, and it is one that policymakers can address with tools that already exist.

The stakes extend well beyond billing mechanics. Untreated depression and anxiety impose costs throughout the health system, from worsened chronic disease control to avoidable hospitalizations, and the shortage of psychiatric clinicians means that simply training more providers cannot close the access gap quickly enough. The authors’ segmented approach treats payment reform not as a single lever but as a sequence of calibrated ones, matched to where each provider organization actually sits on the road from fee-for-service to full accountability for population health. If they are right, aligning incentives with the evidence could turn a proven but underused model into the default way American primary care treats the mind, expanding access to effective behavioral health care at a scale the current system has never achieved.

Subject of Research: Payment policy and adoption of the Collaborative Care Model for behavioral health integration in value-based primary care

Article Title: Evidence-Based Behavioral Health in Value-Based Primary Care: Aligning Incentives to Accelerate Adoption of Collaborative Care

Article References: Huang, J. J., Bhalla, I., & Carlo, A. D. (2026). Evidence-Based Behavioral Health in Value-Based Primary Care: Aligning Incentives to Accelerate Adoption of Collaborative Care. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10868-8

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10868-8

Keywords: Collaborative Care Model, behavioral health integration, value-based payment, primary care, fee-for-service, alternative payment models, return on investment, psychiatry workforce, Medicaid, health policy, depression treatment, shared savings